ASTH Astrana Health Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: ASTH

Price (delayed)

$37.79

Market cap

$2.11B

P/E Ratio

45.53

Dividend/share

N/A

EPS

$0.83

Enterprise value

$2.68B

?
Relative Growth: Rel. Growth: 92
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 68
Relative Profitability: Rel. Profitability: 47

ApolloMed is a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare ...

Highlights
Astrana Health's net income has surged by 61% YoY and by 34% QoQ
The revenue has soared by 59% year-on-year and by 9% since the previous quarter
The debt has surged by 119% year-on-year but it has declined by 8% since the previous quarter
The price to earnings (P/E) is 37% lower than the last 4 quarters average of 72.8 but 4.9% higher than the 5-year quarterly average of 43.4
Astrana Health's quick ratio has decreased by 22% YoY and by 9% from the previous quarter
Astrana Health's gross margin has decreased by 7% YoY
Sector: Healthcare
Industry: Medical Care Facilities
Website: http://www.apollomed.net
Peers: INNV NHC

Key stats

What are the main financial stats of ASTH

ASTH stock price

How has the Astrana Health stock price performed over time
Intraday
5.59%
1 week
10.72%
1 month
-20.68%
1 year
27.54%
YTD
52.32%
QTD
-18.57%

Financial performance

How have Astrana Health's revenue and profit performed over time
Revenue
$3.84B
Gross profit
$402M
Operating income
$100.46M
Net income
$40.55M
Gross margin
10.5%
Net margin
1.1%
Astrana Health's net income has surged by 61% YoY and by 34% QoQ
The revenue has soared by 59% year-on-year and by 9% since the previous quarter
ASTH's gross profit is up by 47% year-on-year and by 7% since the previous quarter
Astrana Health's operating income has increased by 43% YoY and by 16% from the previous quarter

Price vs fundamentals

How does ASTH's price correlate with its fundamentals

Growth

What is Astrana Health's growth rate over time

Valuation

What is Astrana Health stock price valuation
ASTH P/E details
P/E
45.53
P/B
2.54
P/S
0.55
EV/EBIT
20.85
EV/EBITDA
13.42
EV/Sales
0.7
The EPS has surged by 57% year-on-year and by 34% since the previous quarter
The price to earnings (P/E) is 37% lower than the last 4 quarters average of 72.8 but 4.9% higher than the 5-year quarterly average of 43.4
ASTH's price to book (P/B) is 35% lower than its 5-year quarterly average of 3.9 but 15% higher than its last 4 quarters average of 2.2
Astrana Health's equity has increased by 8% YoY and by 3.7% from the previous quarter
ASTH's P/S is 69% below its 5-year quarterly average of 1.8 but 10% above its last 4 quarters average of 0.5
The revenue has soared by 59% year-on-year and by 9% since the previous quarter

Efficiency

How efficient is Astrana Health business performance
Astrana Health's return on equity has increased by 46% YoY and by 31% QoQ
Astrana Health's return on assets has increased by 20% QoQ but it has decreased by 5% YoY
The company's return on invested capital fell by 9% YoY but it rose by 8% QoQ
The return on sales has grown by 6% since the previous quarter

Dividends

What is ASTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ASTH.

Financial health

How did Astrana Health financials performed over time
The total assets is 36% more than the total liabilities
The company's total liabilities has surged by 86% YoY but it fell by 5% QoQ
The total assets has soared by 58% YoY but it has contracted by 3.3% from the previous quarter
The debt is 18% greater than the equity
The debt has surged by 119% year-on-year but it has declined by 8% since the previous quarter
The company's debt to equity has surged by 103% YoY but it fell by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.